ArticleMedicine2025
Relationship between the systemic immune inflammation index and prostate cancer.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of pretreatment systemic immune-inflammation index (SII) in patients with cervical cancer: a meta-analysis.World journal of surgical oncology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between systemic immune inflammatory index (SII) values and prostate cancer remain poorly understood. This study aimed to estimate the association between SII values and the risk of prostate cancer by analyzing the statistics on 10,485 participants in the National Health and Nutrition Examination Survey from 2011 to 2018. The quartile (Q) method was used to divide the participants into 4 groups on the basis of their SII values, from group Q1 (lowest SII values) to group Q4 (highest SII values). The association between the participants' SII values and the risk of prostate cancer was analyzed using weighted logistic regression models and a restricted cubic spline, and further subgroup analysis was conducted by age, body mass index; ethnicity; education level; and smoking, alcohol-drinking, hypertension, hyperlipidemia, and diabetes status. Higher SII values were found to be associated with a higher risk of prostate cancer. In comparison with Q1, the odds ratio of Q4 was 2.26 (95% confidence interval: 1.44-3.55). Subgroup analysis revealed that this positive association was more significant among non-Hispanic black participants than among other participants. In addition, the results of a sensitivity analysis demonstrated that the association between the risk of prostate cancer and the SII values was relatively stable. The SII values were found to be positively associated with the risk of prostate cancer and varied with ethnicity. Nevertheless, further prospective studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.